Sun-273 Patients Treated With Therapeutic Plasma Exchange -a Single Center Experience

Dileep, K S; Alalawi, Fakhriya; Hussein, Rahat; Alhadari, Amna; Mansour, Mark; sony, L.

doi:10.1016/j.ekir.2020.02.809

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case study in Kuwait showed that infliximab (in combination with CYC, MMF and steroids) resulted in sustained remission in a patient with Class IV LN. 52 Other therapies evaluated in the Arabian Gulf region for the treatment of LN included therapeutic plasma exchange in UAE, 53 and intravenous immunoglobulins (IvIg) in Kuwait and Saudi Arabia. 28 , 37 , 54 In the Kuwaiti study, IvIg treatment resulted in stabilisation of renal function and control of symptoms in patients with Class IV LN.…”

Section: Resultsmentioning

confidence: 99%

Literature review of lupus nephritis From the Arabian Gulf region

Al-Shujairi

Elbadawi

Al-Saleh

et al. 2022

Lupus

View full text Add to dashboard Cite

Introduction The severity of lupus nephritis (LN) varies between different ethnicities. However, there are limited data regarding disease severity for LN in patients from the Arabian Gulf region; moreover, there are no treatment guidelines developed specifically for this population. The objective of this review was to characterise the incidence of LN, current treatment practices, the severity of LN, and the pathophysiology and biomarkers associated with LN in the Arabian Gulf region. Methods A literature search using EMBASE was conducted in October, 2021 to identify publications reporting on the incidence, treatment practices, severity, pathophysiology or biomarkers associated with LN, from countries in the Arabian Gulf region (including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates). Additional relevant publications were provided by collaborators. A manual review of the publications was conducted to determine their relevance and data on the outcomes of interest were extracted. Results Of 3705 publications, 54 publications were identified as relevant. LN is one of the most commonly diagnosed renal diseases within the Arabian Gulf and approximately 10%–36% of all renal biopsies are for LN. Treatment patterns within the region appear to vary and generally follow treatment guidelines recommended by the Asia Pacific League of Associations for Rheumatology (APLAR), the European Alliance of Associations for Rheumatology (EULAR) and Kidney Disease Improving Global Outcomes (KDIGO). The majority of patients receive cyclophosphamide for induction therapy, whilst others receive mycophenolate mofetil. Most studies showed that the most frequently diagnosed class of LN within the Arabian Gulf region was Class IV (up to 63% of patients with LN). Sustained or increased levels of serum creatinine and proteinuria; and depressed levels of complement C3/C4 were commonly seen among patients with LN from the Arabian Gulf region. Conclusions This review identified that LN may manifest more severely among patients from the Arabian Gulf region than in other populations, such as Caucasian populations. A greater understanding of LN and the treatment practices within the region, as well as the development of more specific treatment guidelines for this population may help improve outcomes for patients with LN in the Arabian Gulf region.

show abstract